Norfloxacin (MK-0366, AM-715) is a new orally absorbed synthetic organic acid structurally related to nalidixic acid (14, 24) . Its increased potency and expanded antibacterial spectrum compare with those of nalidixic acid (9, 13, 20, 22, 23) , and its desirable pharmacokinetic properties (4) The anaerobic bacterium Clostridium difficile was less susceptible to norfloxacin (MIC90, 128 ,ug/ml) and to nalidixic acid (MIC90, >128 ,ug/ml) than to other agents and was most susceptible to vancomycin (MIC90, 0.5 ,ug/ml). The MIC9os of norfloxacin against all the aerobic isolates tested were less than 1 ,ug/ml, ranging from 0.008 ,ug/ml for E. coli to 0.5 ,ug/ml for Campylobacter fetus subsp. jejuni. 'With MIC90s of >128 ,ug/ml against Salmonella spp., Shigella spp., V. parahaemolyticus, and Yersinia enterocolitica, ampicillin was the least active compound in this study. No significant difference was noted between 01 and non-01 strains of V. cholerae in the spectra of their antimicrobial susceptibility. (Table 1) . Although all the isolates tested in this study were susceptible to the present drug of choice in each case, except for Salmonella enteritidis against ampicillin (MIC90, >128 ,ug/ml), various degrees of bacterial resistance have been reported for virtually all of the marketed compounds tested (3, 11, 15, 16, 18, 29) . Resistance of these various enteric pathogens is defined in vitro by MIC breakpoints of -32 ,g/ml for norfloxacin (submitted for publication), nalidixic acid, ampicillin, co-trimoxazole, and vancomycin; .16 jig/ml for tetracycline and chloramphenicol; -8 jig/ml for erythromycin and clindamycin; and .4 jig/ml for trimethoprim (8, 30) . Except for its apparent lack of intrinsic activity against Clostridium difficile, norfloxacin was substantially more active and possessed a broader spectrum than any of the antimicrobial agents of first choice against enteric pathogens for which these agents are specifically indicated.
The effective use of co-trimoxazole in treating shigellosis and in preventing and managing traveler's diarrhea has been documented (2, 3, 31) . We regret the inadvertent omission of this compound in the present study. It should be pointed out, however, that in several recent reports (8, 13, 15) In previous investigations, the quinoline drugs oxolinic and nalidixic acids, to which norfloxa-VOL. 23, 1983 on June 18, 2017 by guest http://aac.asm.org/ Downloaded from cin is structurally related, were found to be active both in vitro (6, 16) and in vivo (10, 17) against antibiotic-resistant shigellae. Furthermore, the efficacy of oxolinic acid in treating chronic Shigella carriers has been reported (32 Although the development of resistance to nalidixic and oxolinic acids during treatment of urinary tract infections has been shown (1, 7), it is believed that the quinolines still have a significant advantage over other commonly used agents in that resistance appears not to be mediated by R factors (1, 5) , a property which in theory should greatly limit the spread of resistant strains. In a recent study, spontaneous mutation rates of representative bacteria commonly found in the gastrointestinal tract of humans were in each case lower for norfloxacin (ca. 10-12) than for oxolinic acid (ca. 10-6 to 10-10) (12) .
Selective decontamination of the gastrointestinal tract in granulocytopenic patients involving elimination of potentially pathogenic aerobic bacteria and yeasts without disturbing the anaerobic flora has been advocated as an effective means of preventing infections in patients of this kind (34) . Studies in experimental animals (36) and in humans (34) have shown several antibacterial agents, including nalidixic acid and cotrimoxazole, to be suitable for this application. Successful antibiotics appear to be those agents which, like norfloxacin, lack activity against the usual anaerobic bacteria found in the fecal flora (28, 34, 36) . Since the information currently at hand suggests that resistance development among enteric gram-negative bacteria, a major disadvantage of the prophylactic use of antimicrobial agents, is much less likely to occur with norfloxacin than with nalidixic acid, it would appear that evaluation of this new agent in selective suppression of bowel flora in properly selected patients is justifiable.
We believe that the data presented in this report and the accompanying comments should stimulate an interest in further evaluation of norfloxacin as a potential drug for treatable bacterial infections of the gastrointestinal tract.
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